Chemometric Approach to Develop and Validate RP-HPLC Method for Estimation of Erlotinib Hydrochloride in Nano Structured Lipid Carriers

Author(s): Narahari Narayan Palei, Surendran Vijayaraj*, Kuppam Lathasri, Devalapalli Archana, Ponnusamy Rajavel

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Erlotinib hydrochloride is a novel drug for the treatment of lung cancer.

Objective: The objective of the present study was to design an uncomplicated and precise reverse phase high-performance liquid chromatography (RP-HPLC) method and optimize the chromatographic parameters using response surface methodology derived from Box Behnken design. The optimized method was validated for estimating Erlotinib from bulk and nanostructured lipid carriers (NLCs) formulation.

Methods: Independent variables such as flow rate, injection volume and strength of the buffer were optimized in order to decrease retention time and curtail asymmetry factor of Erlotinib. Forced degradation studies were done to determine the stability of the drug. The developed method was validated as per ICH guidelines.

Results: The optimized strength of ortho-phosphoric acid buffer by blending with Acetonitrile (80:20 v/v), flow rate and injection volume were found to be 25mM, 1ml/min, 20µL respectively. Linearity was observed in the concentration range of 1-6 µg/mL. The retention time of Erlotinib was found to be 3.717 minutes. The limit of detection and limit of quantification for Erlotinib were found to be 0.01ng/ml and 1ng/ml, respectively.

Conclusion: The proposed method was found to be a simple and the best method for analysing Erlotinib in nanostructured lipid carriers. Chemometric approach was employed as an effective tool for optimising the chromatographic conditions of the proposed method.

Keywords: Erlotinib hydrochloride, RP-HPLC method, chemometrics, box behnken design, nanostructured lipid carriers, matrix interferences.

[1]
Martindale. The Extra Pharmacopoeia, 31st ed; Pharmaceutical Press: London, 2002.
[2]
United States Pharmacopoeia National Formulary 34th ed.; United States Pharmacopeial convention press: New York,. , 2011.
[3]
National Center for Biotechnology Information. PubChem Compound Database,CID=176871 https://pubchem.ncbi.nlm.nih.gov/compound/176871(Accessed on: May 28. 2018).
[4]
Siddiqui, M.R.; Alothman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab. J. Chem., 2017, 10, S1409-S1421.
[5]
Alothman, Z.A.; Rahman, N.; Siddiqui, M.R. Review on pharmaceutical impurities, stability studies and degradation products. Rev. Adv. Sci. Eng., 2013, 2, 155-166.
[6]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accredit. Qual. Assur., 2006, 11, 69-74.
[7]
Rajesh, V.; Anupama, B.; Jagathi, V.; Varaprasad, K. High performance thin layer chromatographic method for estimation of Erlotinib hydrochloride as buk drug. Int. J. Biol. Med. Res., 2011, 2, 433-435.
[8]
Usha Rani, G.; Chandrasekhar, B.; Devanna, N. Extractive colorimetric method development and validation for Erlotinib in bulk and tablet dosage form. J. Appl. Pharm. Sci., 2011, 1, 176-179.
[9]
Rajesh, V.; Jagathi, V.; Sindhuri, K.; Devala Rao, G. Spectrofluorimetric method for the estimation of erlotinib hydrochloride in pure and pharmaceutical formulations. E-J. Chem., 2011, 8, S304-S308.
[10]
Erin, R.L.; Swain, S.M.; Tan, A.R.; Fiqq, W.D.; Sparreboom, A. Liquid chromatographic determination of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Chromatogr. B., 2003, 796, 181-188.
[11]
Yadav, N.K.; Raghuvanshi, A.; Sharma, G.; Sharma, G.; Beg, S.; Katare, O.P.; Nanda, S. QbD-Based development and validation of a stability indicating HPLC Method for Estimating Ketoprofen in bulk drug and proniosomal vesicular system. J. Chromatogr. Sci., 2015, 54(3), 377-389.
[12]
Latha, S.T.; Ananda Thangadurai, S.; Jambulingam, M.; Sereya, K.; Kamalakannan, D.; Anilkumar, M. Development and validation of RP-HPLC method for the estimation of Erlotinib in pharmaceutical formulation. Arab. J. Chem., 2017, 10, S1138-S1144.
[13]
Ferreira, S.L.C.; Bruns, R.E.; Ferreira, H.S.; Matos, G.D.; David, J.M.; Brandao, G.C.; Silva, E.G.P.; Portugal, L.A.; Dos Reis, P.S.; Souza, A.S.; Dos Santos, W.N.L. Box-Behnken design: An alternative for the optimization of analytical methods. Anal. Chim. Acta, 2007, 597(2), 179-186.
[14]
Massart, D.L.; Vandeginste, B.G.M.; Buydens, L.M.C.; Jong, S.; Lewi, P.J.; Smeyers-Verbeke, J. Handbook of Chemometrics and Qualimetrics: Part A; Elsevier: Amsterdam, 1977.
[15]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH, Q1A (R2): Stability Testing of New Drug Substances and Products (revision 2), International Conference on Harmonization., Geneva, Switzerland, February. 2003.
[16]
Blessy, M.; Ruchi, D.P.; Prajapati, P.N.; Agrawal, Y.K. Development of forced degradation and stability indicating studies of drugs- A review. J. Pharm. Anal., 2014, 4(3), 159-165.
[17]
Reynolds, D.W.; Kevin, L.F.; Mullaney, J.F.; Alsante, K.M.; Todd, D.H.; Michael, G.M. Available guidance and best practices for conducting forced degradation studies. Pharm. Technol., 2002, 26(2), 48-56.
[18]
U.S. Department of Health and Human Services.Food and drug administration, Centre for Drug evaluation and Research (CDER), centre for Biologics Evaluation and Research (CBER). Guidance for industry, Q2 (R1) Validation of Analytical Procedures: Methodology International Conference on Harmonization, Geneva November. 2005.
[19]
International Conference of Harmonization for Technical requirements for the Registration of Drugs for Human use. ICH, Q2B Validation of Analytical Procedure; Methodology, Geneva, Switzerland,May 1997.
[20]
International Federation of Pharmaceutical Manufactures and Associations (IFPMA) Validation of analytical procedures: text and methodology. Proceedings of the International Conference on Harmonization, Methodology Q2 (R1) Geneva, Switzerland. ICH,Switzerland: 1996.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [210 - 219]
Pages: 10
DOI: 10.2174/1573412915666181113130245
Price: $65

Article Metrics

PDF: 19
HTML: 3
EPUB: 1
PRC: 1